Publication

Analysis of current perioperative management with Haemate((R)) P/Humate P-(R) in von Willebrand disease: Identifying the need for personalized treatment

OPTI-CLOT WIN Study Grp, Hazendonk, H. C. A. M., Heijdra, J. M., de Jager, N. C. B., Veerman, H. C., Boender, J., van Moort, I., Mathot, R. A. A., Meijer, K., Laros-van Gorkom, B. A. P., Eikenboom, J., Fijnvandraat, K., Leebeek, F. W. G. & Cnossen, M. H., May-2018, In : Haemophilia. 24, 3, p. 460-470 11 p.

Research output: Contribution to journalArticleAcademicpeer-review

  • OPTI-CLOT WIN Study Grp
  • H. C. A. M. Hazendonk
  • J. M. Heijdra
  • N. C. B. de Jager
  • H. C. Veerman
  • J. Boender
  • I. van Moort
  • R. A. A. Mathot
  • K. Meijer
  • B. A. P. Laros-van Gorkom
  • J. Eikenboom
  • K. Fijnvandraat
  • F. W. G. Leebeek
  • M. H. Cnossen

IntroductionPatients with Von Willebrand disease (VWD) are regularly treated with VWF-containing concentrates in case of acute bleeding, trauma and dental or surgical procedures.

AimIn this multicentre retrospective study, current perioperative management with a von Willebrand factor (VWF)/Factor VIII (FVIII) concentrate (Haemate((R)) P) in patients with VWD was evaluated.

Patients/MethodsPatients with VWD undergoing minor or major surgery between 2000 and 2015, requiring treatment with a VWF/FVIII concentrate (Haemate((R)) P), were included. Achieved VWF activity (VWF:Act) and FVIII during FVIII-based treatment regimens were compared to predefined target levels in national guidelines.

ResultsIn total, 103 patients with VWD (148 surgeries) were included: 54 type 1 (73 surgeries), 43 type 2 (67 surgeries) and 6 type 3 (8 surgeries). Overall, treatment resulted in high VWF:Act and FVIII levels, defined as 0.20IU/mL above predefined levels. In patients with type 1 VWD, respectively, 65% and 91% of trough VWF:Act and FVIII levels were higher than target levels. In patients with type 2 and type 3 VWD, respectively, 53% and 57% of trough VWF:Act and 72% and 73% of trough FVIII levels were higher than target level. Furthermore, FVIII accumulation over time was observed, while VWF:Act showed a declining trend, leading to significantly higher levels of FVIII than VWF:Act.

ConclusionHigh VWF:Act and accumulation of FVIII were observed after perioperative FVIII-based replacement therapy in patients with VWD, both underlining the necessity of personalization of dosing regimens to optimize perioperative treatment.

Original languageEnglish
Pages (from-to)460-470
Number of pages11
JournalHaemophilia
Volume24
Issue number3
Publication statusPublished - May-2018

    Keywords

  • individualized medicine, surgery, therapy, von Willebrand Disease, von Willebrand factor (MESH entry database), FACTOR CONCENTRATE, FACTOR-VIII, VENOUS THROMBOEMBOLISM, INVASIVE PROCEDURES, ORTHOPEDIC-SURGERY, ELECTIVE SURGERY, FVIII, VWF, PHARMACOKINETICS, CLASSIFICATION

View graph of relations

Download statistics

No data available

ID: 65349313